Evidence map›Paper›PMID 40789024›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

Structural insights into VRC01-class bnAb precursors with diverse light chains elicited in the IAVI G001 human vaccine trial.

Xiaohe Lin, Christopher A Cottrell, Oleksandr Kalyuzhniy, Ryan Tingle, Michael Kubitz, Danny Lu, Meng Yuan, William R Schief, Ian A Wilson

Abstract readClinical Trial, Phase I
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Deep learning-enabled scaffolding of spatial arrays of PfCSP epitopes.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Antibody feedback establishes an affinity brake in the germinal center.bioRxiv : the preprint server for biology · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Xiaohe LinDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037.ORCID 0000-0001-6761-3897
Christopher A CottrellCenter for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037.ORCID 0000-0002-3364-3083
Oleksandr KalyuzhniyCenter for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037.ORCID 0000-0002-5273-1951
Ryan TingleCenter for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037.ORCID 0000-0003-2874-7010
Michael KubitzCenter for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037.ORCID 0000-0002-3917-453X
Danny LuCenter for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037.ORCID 0000-0002-2340-3377
Meng YuanDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037.ORCID 0000-0001-9754-4503
William R SchiefCenter for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037.ORCID 0000-0002-1120-0150
Ian A WilsonDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037.ORCID 0000-0002-6469-2419

Funding

Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6M
X-ray Absorption Spectroscopy (XAS) pp.711-759P41GM103393 · NIGMS · STANFORD UNIVERSITY · PI HODGSON, KEITH O · 2012 to 2019
$30.6M
Bill and Melinda Gates Foundation (GF) CAVDNIAID NIH HHS UM1 AI144462NIGMS NIH HHS P41 GM103393
6 · The paper itself

Abstract

The development of germline-targeting vaccines represents a potentially transformative strategy to elicit broadly neutralizing antibodies (bnAbs) against HIV and other antigenically diverse pathogens. Here, we report on structural characterization of vaccine-elicited VRC01-class bnAb precursors in the IAVI G001 Phase 1 clinical trial with the eOD-GT8 60mer nanoparticle as immunogen. High-resolution X-ray structures of eOD-GT8 monomer complexed with Fabs of five VRC01-class bnAb precursors with >90% germline identity revealed a conserved mode of binding to the HIV CD4-binding site via IGHV1-2-encoded heavy chains, mirroring mature bnAb interactions. The light-chain V-gene diversity emulated VRC01 bnAbs and stabilized antigen engagement, while their conserved five-residue LCDR3 motifs prevented steric clashes. Notably, the VRC01-class bnAb precursors accommodated the N276 glycan, a key barrier in HIV Env recognition, through structural rearrangements in HCDR3 or LCDR1, despite its absence in the immunogen. Surface plasmon resonance analysis showed that 87% of elicited antibodies retained glycan binding capacity, albeit with reduced affinity. These findings validate the ability of eOD-GT8 60mer nanoparticles to prime VRC01-class bnAb precursors with native-like paratopes but with intrinsic glycan adaptability. Structural mimicry of mature bnAbs was observed even with limited somatic hypermutation, indicating that critical features are encoded in the germline repertoire. The structures highlight how germline-encoded features drive bnAb-like recognition at early stages. This work provides molecular evidence supporting germline targeting in humans and provides guidance for designing booster immunogens to shepherd affinity maturation toward broad neutralization.

Indexed as

AIDS VaccinesAntibodies, MonoclonalAntibodies, NeutralizingHIV AntibodiesHIV InfectionsImmunoglobulin Light ChainsBroadly Neutralizing AntibodiesCrystallography, X-RayHIV-1HumansAIDS VaccinesAntibodies, MonoclonalAntibodies, NeutralizingBroadly Neutralizing AntibodiesHIV AntibodiesImmunoglobulin Light ChainsVRC01 monoclonal antibodygermline-targeting vaccineHIV CD4-binding siteN276 glycan accommodationVRC01-class antibodiesX-ray crystallography

Identifiers

PMID40789024
PMCPMC12377726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.